A translocation in the gene encoding the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), leading to the expression of ALK fusion proteins, was first reported in NSCLC patients in 2007[8, 9]. This evidence concerns the gene ALK and non-small cell lung carcinoma.